Catalog No.
Product Name
Application
Product Information
Citations
-
Overoxidized By-product of Lansoprazole
Lansoprazole sulfone N-Oxide is an overoxidized by-product generated during the synthesis of the proton pump inhibitor Lansoprazole. This compound is relevant for research into gastrointestinal conditions, such as duodenal and gastric ulcers, reflux esophagitis, and Zollinger–Ellison syndrome. Its study may provide insights into the metabolic pathways and potential therapeutic implications related to proton pump inhibition. -
Proton Pump Inhibitor
Zastaprazan citrate is a proton pump inhibitor that functions as a potent potassium-competitive acid blocker. This compound is primarily utilized in research related to gastrointestinal inflammatory disorders and gastric acid-related conditions, including gastroesophageal reflux disease. Its ability to effectively inhibit gastric acid secretion makes it a valuable tool for studying underlying mechanisms of these diseases. -
Proton Pump Inhibitor
Azeloprazole sodium is a potent proton pump inhibitor (PPI) that effectively reduces gastric acid secretion. This compound is primarily used in research related to gastroesophageal reflux disease (GERD), facilitating studies on acid-related gastrointestinal disorders and therapeutic interventions. Its mechanism of action provides valuable insights into the regulation of gastric proton pumps and their role in acid-mediated conditions. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan hydrochloride is a potassium-competitive acid inhibitor that selectively targets H+, K+-ATPase, providing a mechanism of action distinct from traditional proton pump inhibitors. By reversibly binding in a potassium-competitive manner, Abeprazan hydrochloride effectively reduces gastric acid secretion without requiring acid activation. This compound is being investigated for its therapeutic potential in treating various acid-related gastrointestinal disorders. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan is a potassium-competitive acid inhibitor primarily targeting the H+, K+-ATPase enzyme. By reversibly binding to this enzyme through potassium-competitive ionic interactions, it effectively reduces gastric acid secretion without the need for acid activation. Abeprazan is being developed as a potential alternative to traditional proton pump inhibitors for the management of acid-related disorders, providing a novel approach to acid control in clinical applications. -
Proton Pump Inhibitor
Zastaprazan is a potent proton pump inhibitor that functions as a potassium-competitive acid blocker. It is utilized in research related to gastrointestinal inflammatory diseases and gastric acid-related conditions, including gastroesophageal reflux disease. This compound provides valuable insights into mechanisms of acid secretion and potential therapeutic approaches in the treatment of acid-related disorders. -
Stable Isotope
Abscisic acid-d6 is a deuterium-labeled derivative of abscisic acid, functioning as a stable isotope. This compound is known for its ability to inhibit the proton pump (H+-ATPase), making it a valuable tool for investigating physiological processes regulated by abscisic acid. Its applications extend to studying plant stress responses, signal transduction pathways, and metabolic regulation in various biological systems. -
Proton-pump Inhibitor
5-Hydroxylansoprazole is a metabolite of Lansoprazole, acting as a proton-pump inhibitor. This compound is instrumental in reducing gastric acid secretion, thereby aiding in the treatment of various peptic disorders. Its primary application in research includes the investigation of acid-related gastrointestinal conditions and the pharmacokinetics of proton-pump inhibitors. -
Proton Pump Inhibitor
Padoprazanum is a proton pump inhibitor that works by irreversibly blocking the H+/K+ ATPase enzyme in the gastric parietal cells. This inhibition effectively reduces gastric acid secretion, making it useful in the treatment of various acid-related gastrointestinal disorders. Key research applications include the investigation of acid secretion mechanisms and the study of therapeutic strategies for conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. -
Proton Pump Inhibitor
Padoprazanum hydrochloride is a proton pump inhibitor that selectively targets gastric proton pumps, reducing acid secretion in the stomach. This compound demonstrates significant efficacy in the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. Its unique mechanism of action makes it a valuable tool for researchers studying gastric secretion and related gastrointestinal conditions. -
Proton Pump Inhibitor
Omeprazole magnesium is an orally active proton pump inhibitor (PPI) that effectively suppresses gastric acid secretion. It is utilized in research related to acid reflux symptoms and frequent heartburn, making it a valuable tool for investigating gastrointestinal disorders and related therapeutic interventions. -
Proton Pump Inhibitor
Linaprazan mesylate is a proton pump inhibitor that targets the H+,K+ -ATPase enzyme in the gastric mucosa through competitive binding with potassium ions. With an IC50 value of 1.0 ± 0.2 μM, it exhibits potent inhibitory effects on gastric acid secretion. This compound is particularly applicable in studies related to gastroesophageal reflux disease and reflux esophagitis, facilitating research on its therapeutic potential. -
Stable Isotope
Esomeprazole-d6 sodium is a deuterium-labeled derivative of Esomeprazole. This compound functions primarily as a proton pump inhibitor, effectively reducing gastric acid secretion by inhibiting the H+, K+-ATPase enzyme in gastric parietal cells. Esomeprazole-d6 sodium is valuable for research applications focused on gastroesophageal reflux disease, enabling the study of metabolic pathways and pharmacokinetics in related therapeutic investigations. -
H+, K+-ATPase Inhibitor
S 1924 is a potent H+, K+-ATPase inhibitor, demonstrating IC50 values of 10.3 μM at pH 7.4 and 1.6 μM at pH 6.0. This compound effectively modulates gastric acid secretion, making it valuable in research related to gastrointestinal physiology and pharmacology. Its specificity for H+, K+-ATPase makes S 1924 a useful tool for investigating proton pump mechanisms and related therapeutic targets. -
Proton Pump Inhibitor
AGN-201904Z is a novel proton pump inhibitor that effectively inhibits gastric acid secretion. This compound demonstrates enhanced and sustained acid suppression effects compared to traditional agents such as esomeprazole. AGN-201904Z is valuable for research applications aimed at studying gastric disorders and evaluating the physiological impacts of prolonged acid suppression. -
Proton Pump Inhibitor
Saviprazole is a proton pump inhibitor that effectively reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. This compound demonstrates significant biological activity in the treatment of gastrointestinal diseases, particularly in conditions such as gastric ulcers and acid reflux. Its application in research provides valuable insights into acid-related disorders and potential therapeutic interventions. -
Proton Pump Inhibitor
Tiludronate, a bisphosphonate with proton pump inhibitor activity, primarily targets the osteoclast vacuolar H(+)-ATPase to regulate bone metabolism. It exhibits potent antiresorptive and anti-inflammatory properties, making it valuable for studying metabolic bone disorders. Its role in inhibiting osteoclast function positions Tiludronate as a critical tool for research focused on bone health and related diseases. -
Proton Pump Inhibitor
Padoprazanum fumarate is a proton pump inhibitor that targets the H+/K+ ATPase enzyme in gastric parietal cells, effectively reducing gastric acid secretion. It demonstrates notable efficacy in the treatment of conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. This compound serves as a valuable tool for researchers investigating gastric acid regulation and related gastrointestinal disorders. -
Proton Pump Inhibitor
WY-47766 is a potent proton pump inhibitor that targets the gastric H+/K+ ATPase enzyme. Its primary mechanism involves the irreversible binding to the enzyme, leading to a significant reduction in gastric acid secretion. WY-47766 is utilized in research applications focused on understanding gastric physiology, acid secretion disorders, and the development of therapeutic strategies for related gastrointestinal diseases. -
Proton Pump Inhibitor
(R)-(+)-Pantoprazole sodium is a potent proton pump inhibitor that selectively targets the H+/K+ ATPase enzyme in gastric parietal cells. This compound is primarily utilized in research related to gastroesophageal reflux disease, aiding in the elucidation of gastric acid secretion mechanisms and therapies. Its ability to effectively reduce gastric acidity makes it a valuable tool for studying acid-related disorders and developing therapeutic strategies. -
proton pump Inhibitor
AGN-201904 is a proton pump inhibitor that functions as an omeprazole prodrug. This compound has shown potential in delaying aging processes and is effective in the prevention and inhibition of peptic ulcers. Its biological activity makes it a valuable tool in research focused on gastrointestinal health and the mechanisms of aging. -
H+/K+-ATPase Inhibitor
KR-60436 is a reversible inhibitor of H+/K+-ATPase, effectively obstructing proton and potassium transport across cellular membranes. This compound has demonstrated potent inhibition of CYP1A2 substrate metabolism, making it a valuable tool for studying gastric proton pump activity and its implications in drug metabolism. Its utility extends to drug interaction studies and the investigation of gastrointestinal pharmacology. -
Proton Pump Inhibitor
SKF96067 is a reversible inhibitor of the gastric H+/K+-ATPase, primarily targeting proton pumps involved in gastric acid secretion. This compound demonstrates significant biological activity in reducing gastric acid production, making it useful in research related to gastrointestinal diseases and acid-related disorders. Its modulation of proton pump activity aids in elucidating mechanisms of acid secretion regulation and the potential therapeutic effects on related pathologies. -
Cinnamic Acid Derivative
2-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative that acts as an inhibitor of the proton pump (H+/K+-ATPase), leading to a reduction in gastric acid secretion. This compound has demonstrated biological activity in improving delayed gastric emptying and is valuable for research on gastric pathologies, including acute gastritis and gastric ulcers. Its unique properties make it an important reagent for studies investigating gastric health and related disorders. -
Proton Pump Inhibitor
Nepaprazole is a proton pump inhibitor that targets H+/K+-ATPase activity, significantly reducing gastric acid secretion. It demonstrates inhibitory effects in isolated rabbit gastric mucosal microsomes with IC50 values of 5.8 μM and 9.9 μM at pH 6.0 and pH 7.4, respectively. This compound is primarily utilized in research related to peptic ulcer diseases, providing insights into gastric acid regulation and potential therapeutic interventions. -
Proton Pump Inhibitor
Tenatoprazole sodium is a potent proton pump inhibitor that specifically targets the hog gastric H+/K+-ATPase, exhibiting an IC50 of 6.2 μM. This compound effectively decreases gastric acid secretion, making it valuable for research in gastrointestinal disorders and related therapeutic applications. Its mechanism of action positions it as a useful tool for studying the regulation of gastric acidity and the underlying pathways involved in acid-related diseases. -
Proton Pump Inhibitor
S3337 is a potent inhibitor of H+, K+-ATPase, a key enzyme responsible for regulating gastric acid secretion. By targeting this proton pump, S3337 effectively reduces gastric acid production, making it valuable for research into acid-related disorders. Its primary applications include studies on gastritis, peptic ulcers, and gastroesophageal reflux disease (GERD). -
H+/K+-ATPase Inhibitor
DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase, exhibiting an IC50 value of 5 µM. This compound effectively inhibits gastric acid secretion by blocking the proton pump in the gastric mucosa, demonstrating significant protective effects against duodenal ulcers induced by Cysteamine, and gastric ulcers induced by Indomethacin and Aspirin, with EC50 values of 6, 3.1, and 4 mg/kg, respectively. DBM-819 serves as a valuable tool in research focused on ulcer prevention and gastroprotection. -
Na+/K+ ATPase inhibitor
Ro 18-5364 is a selective inhibitor of gastric H+/K+ ATPase, primarily targeting the enzyme's activity. It demonstrates significant inhibition, particularly at lower pH levels, making it a valuable tool for studying gastric physiology. The compound's effects on enzyme activity, proton transport, and binding interactions can be assessed through various experimental methodologies, providing insights into its mechanism of action and potential therapeutic applications in conditions related to proton pump regulation. -
Proton Pump Inhibitor
A 80915A is a potent proton pump inhibitor derived from seminaphthoquinone, which is produced by the Streptomyces species. It functions primarily by inhibiting Na+/K+ ATPase, a key enzyme involved in gastric acid secretion. This compound is valuable for research applications focused on understanding gastrointestinal physiology and exploring therapeutic strategies for acid-related disorders. -
Proton Acceptor
2,6-Diphenylpyridine serves as a proton acceptor and a tridentate [C^N^C] dianionic ligand. This compound facilitates efficient proton transfer at the interface of two immiscible electrolyte solutions. Its ability to form mononuclear and binuclear complexes with gold(III) enhances its utility in studies of electrochemical ion transfer kinetics and organometallic chemistry. 2,6-Diphenylpyridine is valuable for research applications involving coordination chemistry and catalytic processes. -
Photolabile Proton Donor
DMNB (6-Nitroveratraldehyde) functions as a photolabile proton donor, releasing acidic species upon excitation at a wavelength of 405 nm. It is employed in the synthesis of no-carrier-added 6-[18F]fluoro-L-DOPA (6-FDOPA) and is useful for preparing o-nitroaryl-bis(5-methylfur-2-yl)methanes and alpha-asarone. Additionally, DMNB is relevant in studies involving the non-homologous end joining (NHEJ) pathway for DNA double-strand break repair and is applicable in PET imaging of the dopaminergic system. -
Stable Isotope
Pantoprazole-d4 is a deuterated derivative of Pantoprazole, a potent proton pump inhibitor that targets the H+/K+-ATPase enzyme with an IC50 of 6.8 μM. This stable isotope is utilized primarily in pharmacokinetic studies and metabolic research to enhance the accuracy of drug absorption and distribution analysis. Pantoprazole exhibits anti-secretory and anti-ulcer properties, while its combination with Doxorubicin has been shown to significantly increase tumor growth delay, underscoring its potential utility in cancer research. -
Pantoprazole Impurity
Pantoprazole N-oxide is a known impurity associated with the synthesis of Pantoprazole, a proton pump inhibitor (PPI) utilized in the treatment of conditions linked to excessive gastric acid, including gastric ulcers and gastroesophageal reflux disease (GERD). This compound is valuable for analytical research and quality control processes, aiding in the characterization and assessment of Pantoprazole formulations. Its presence in pharmaceutical development highlights the importance of monitoring impurities to ensure product safety and efficacy. -
H+, K+-ATPase Inhibitor
Esomeprazole magnesium, a potent H+, K+-ATPase inhibitor, is utilized in research related to upper intestinal disorders and gastroesophageal reflux disease. Its primary mechanism involves the inhibition of proton pumps, leading to decreased gastric acid secretion. Additionally, Esomeprazole magnesium exhibits properties as an exosome inhibitor by blocking exosome release through the inhibition of vacuolar H+-ATPases, making it valuable for studies on cellular communication and disease progression. -
Proton Pump Inhibitor
Ilaprazole sodium is a potent proton pump inhibitor that irreversibly targets H+/K+-ATPase, demonstrating a dose-dependent inhibition with an IC50 of 6 μM in rabbit parietal cell assays. This compound is primarily utilized in research focused on gastric ulcers, providing insights into gastric acid secretion regulation. Additionally, Ilaprazole sodium acts as an effective inhibitor of TOPK (T-lymphokine-activated killer cell-originated protein kinase), facilitating studies related to immune responses and cancer therapeutics. -
Proton Pump inhibitor
Azeloprazole is a proton pump inhibitor that targets the H+,K+-ATPase enzyme, effectively reducing gastric acid secretion. It has demonstrated significant efficacy in preclinical models, including a dog's gastric fistula, where it outperformed esomeprazole in terms of duration of action. This compound is useful in studying acid-related diseases and exploring mechanisms of gastric acid regulation.
